DOCSLIB.ORG

Progesterone Effects During Sequential Hormone Replacement Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progesterone Effects During Sequential Hormone Replacement Therapy European Journal of Endocrinology (2003) 148 571–577 ISSN 0804-4643 CLINICAL STUDY Progesterone effects during sequential hormone replacement therapy Lotta Andre´en, Mari Bixo, Sigrid Nyberg, Inger Sundstro¨m-Poromaa and Torbjo¨rn Ba¨ckstro¨m Department of Clinical Sciences, Obstetrics and Gynecology, Umea˚ University, Umea˚, Sweden (Correspondence should be addressed to T Ba¨ckstro¨m, Department of Obstetrics and Gynecology, University Hospital, S-901 87 Umea˚, Sweden; Email: [email protected]) Abstract Objective: The aim was to investigate the effect on mood and the physical symptoms of two dosages of natural progesterone and a placebo in postmenopausal women with and without a history of premenstrual syndrome (PMS). Design: A randomized, placebo-controlled, double-blind, crossover study was performed. Method: Postmenopausal women ðn ¼ 36Þ with climacteric symptoms were recruited. They received 2 mg estradiol continuously during three 28-day cycles. Vaginal progesterone suppositories with 800 mg/day, 400 mg/day, or placebo were added sequentially for 14 days per cycle. Daily symptom ratings using a validated rating scale were kept. Results: Women without a history of PMS showed cyclicity in both negative mood and physical symp- toms while on 400 mg/day progesterone but not on the higher dose or the placebo. Women without a history of PMS had more physical symptoms on progesterone treatment compared with placebo. Women with prior PMS reported no progesterone-induced symptom cyclicity. Conclusion: In women without prior PMS natural progesterone caused negative mood effects similar to those induced by synthetic progestogens. European Journal of Endocrinology 148 571–577 Introduction its conversion to allopregnanolone, active on the GABAA receptor (10). A paradox has emerged as all synthetic progestogens It is well known that sequential hormone replacement tested so far induce negative mood effects in humans, therapy (HRT) causes cyclicity in mood and physical while natural progesterone seems to have the opposite symptoms similar to those symptoms encountered effect on mood, at least in animal experiments. So far, during ovulatory cycles and in premenstrual syndrome in humans, most studies on mood and natural pro- (PMS). It seems plausible to conclude that it is the gesterone have focused on treating PMS. These con- addition of synthetic progestogens in HRT that provokes trolled trials have been unable to confirm any these negative mood symptoms (1–5). superiority of progesterone to placebo in terms of the One major question, however, is whether or not lessening of PMS symptoms (11, 12). Instead, there natural progesterone has the same effect on mood as are indications that natural progesterone is involved synthetic progestogens (6). In laboratory animals, in negative mood changes. The recurrence of physical some of progesterone’s metabolites, i.e. 3a-OH-5a-preg- and psychological symptoms in the late luteal phase nan-20-one (allopregnanolone) and 3a-OH-5b-preg- in women with PMS is related to increased progester- nan-20-one (pregnanolone), have barbiturate- and one serum concentrations during this period (13). benzodiazepine-like effects mediated through their Between menstrual cycles, an intra-individual worsen- binding to the gamma aminobutyric acid (GABAA) ing of symptoms is related to higher progesterone receptor complex in the brain, thereby eliciting hypno- serum concentrations (14). An important question tic, anxiolytic, and anti-epileptic effects (7, 8). In therefore arises: is progesterone qualitatively different humans, progesterone can, in large doses, induce from progestogens in its ability to influence mood or anesthesia, and this effect is mediated via the metab- are the reported differences in symptom-provoking olism of progesterone to allopregnanolone and pregna- effects due to differences in progesterone/progestogen nolone (8, 9). Similarly, the acute anxiolytic effect of dose? To our knowledge, natural progesterone has not progesterone in laboratory animals is mediated through previously been investigated with respect to its possible q 2003 Society of the European Journal of Endocrinology Online version via http://www.eje.org Downloaded from Bioscientifica.com at 10/03/2021 03:38:53AM via free access 572 L Andre´en and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003) 148 mood-improving or -deteriorating effects in postmeno- deterioration prior to menstruation which decreased pausal women on sequential HRT. and disappeared within 4 days after the onset of men- It has been reported that women with a history of strual bleeding. The influence of PMS symptoms on PMS, during their fertile life, respond with less positive daily life was graded, and women whose family and more negative mood symptoms compared with relations, social activities, or work were negatively controls under treatment with progestogens (3, 5). affected by the symptoms were considered to have a However, women with PMS seem to be less sensitive history of PMS. to the sedative effects of pregnanolone, a progesterone metabolite, and benzodiazepines compared with con- Study design trols (15, 16). In terms of negative mood symptoms, they seem to respond more strongly to oral contracep- The effect of two different progesterone doses on symp- tives than women who do not have PMS (17). Thus, a tom cyclicity was evaluated in a randomized, placebo- history of PMS may be of importance for the severity of controlled, double-blind, crossover design. The women reaction to progesterone in postmenopausal women were divided into three groups and treated for three (3). This motivates recording the presence of PMS 28-day cycles. Estradiolvalerat at a dose of 2 mg (Apote- during fertile life in postmenopausal women. ket AB, Stockholm, Sweden (the national pharmacy The objective of this randomized, double-blind, pla- company)) was given continuously throughout the cebo-controlled study was to investigate if the addition study period. Progesterone vaginal suppositories were of vaginal progesterone to estrogen treatment induces added on days 15–28 of each cycle. One group started effects on mood and physical symptoms and whether the sequential treatment with 800 mg/day progesterone, or not these are dose-dependent. Furthermore, the the second group with 400 mg/day progesterone, and study aimed to evaluate whether a history of PMS influ- the third group with placebo vaginal suppositories. All ences the potential adverse mood effects induced by suppositories were given as 400 mg, 200 mg, or placebo vaginal progesterone. twice a day. A crossover to a new treatment was carried out after each cycle. The two progesterone doses chosen are the two pharmaceutical preparations available in Materials and methods Sweden at present, and it has been shown that there is Subjects a significant difference in progesterone serum concen- trations between the two doses (19). The vaginal formu- Thirty-six women with climacteric symptoms were lation was a waxy suppository containing progesterone recruited and randomly assigned to treatment in a in a base of semi-synthetic glycerides produced from double-blind, crossover study. Subjects were more hydrogenated vegetable oil by interesterification. than 6 months postmenopausal and had not used The vaginal pessaries were prepared by Apoteket AB, any HRT for the past 3 months prior to inclusion in Production and Laboratories. The suppositories were the study. None were receiving any steroid treatment, made to appear identical. Packing and randomization and all had an intact uterus and no contraindications were done by the pharmacy at Umea˚ University to HRT. They had no history of psychiatric illness and Hospital. had not been treated with psychopharmacologic In women with climacteric symptoms, estrogen is drugs within the past 6 months. Subjects with ongoing known to decrease the vasomotor symptoms during psychiatric illness were excluded by the use of PRIME- the first month of treatment. In parallel with MD. PRIME-MD has been developed to help primary the improvement in vasomotor symptoms there is care physicians to screen, evaluate, and diagnose an increase in well-being due to relief of symptoms. mental disorder. This diagnostic tool is constructed to To avoid interference with the mood changes related conform to Diagnostic and Statistical Manual of to improvements in vasomotor symptoms, a run-in Mental disorders, Fourth edition (DSM-IV) criteria and cycle with an ordinary sequential HRT treatment was has been validated for use in a primary care setting given in order to treat the vasomotor symptoms before (18). PRIME-MD is fully described elsewhere (18). The the study proper started (20). Therefore, the study agreement between PRIME-MD and independent began with a 28-day run-in cycle where the patients psychiatric diagnoses guided by a structured interview were treated with 2 mg estradiolvalerat daily and is generally excellent across modules, with an overall 10 mg medroxyprogesterone (MPA) on days 15–28 of accuracy of 88% (18). Before inclusion, patients gave the cycle. The drawback of this procedure is that all their written consent and agreed to keep a daily cycles following a progestogen treatment will have a record of their symptoms. They also underwent a physi- 3- to 4-day period at the beginning of the next cycle cal and gynecological examination, including a routine when the symptoms from the previous cycle decline (3). vaginal ultrasonography. The primary outcome measure was the daily symptom The study included women with and without a his- ratings made by the patients throughout the study. tory of PMS. Premenstrual symptoms during fertile We used a modified form of the cyclicity diagnoser life were defined by a retrospective report of mood ((CD) Diagnoskonsuelt, Umea˚, Sweden), an instrument www.eje.org Downloaded from Bioscientifica.com at 10/03/2021 03:38:53AM via free access EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003) 148 Progesterone effects during HRT 573 for diagnosing cyclic symptoms that has been validated (PMS vs non-PMS), progesterone dose (placebo, for the diagnosis of PMS (21) but also used to evaluate 400 mg, or 800 mg), and progesterone day (days HRT-related symptom changes in postmenopausal 15–28).
Load more

Recommended publications
  • Kava (Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue Against Ischemic Damage in Rodents
    5 Refs: Arletti R et al, Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology 143(1), 15-19, 1999. Berger F, Handbuch der drogenkunde . Vol 2, Maudrich, Wien, 1950. Martinez M, Les plantas medicinales de Mexico . Cuarta Edicion Botas Mexico , p119, 1959. Tyler VE et al, Pharmacognosy , 9 th edition, Lea & Febiger, Philadelphia, 1988. KAVA ( Piper methysticum ) - A REVIEW The Kava plant (Piper methysticum) is a robust, well-branching and erect perennial shrub belonging to the pepper family (Piperaceae). The botanical origin remains unknown, although it is likely that early Polynesian explorers brought the plant with them from island to island. Numerous varieties of Kava exist, and today it is widely cultivated in several Pacific Island countries both for local use as well as the rapidly growing demand for pharmaceutical preparations. The dried rhizomes (roots) are normally used. The first description to the western world of the ceremonial use of an intoxicating beverage prepared from Kava was made by Captain James Cook following his Pacific voyage in 1768. The drink, prepared as an infusion in an elaborate manner after first chewing the root, is consumed on formal occasions or meetings of village elders and chiefs, as well as in reconciling with enemies and on a more social basis. It remains an important social custom in many Pacific Island countries today. Most of the islands of the Pacific possessed Kava prior to European contact, particularly those encompassed by Polynesia, Melanesia and Micronesia. After drinking the Kava beverage a pleasantly relaxed and sociable state develops, after which a deep and restful sleep occurs.
    [Show full text]
  • Alternative Treatments for Depression and Anxiety
    2019 PCB Conference: Strickland Benzodiazepines (BZDs), Herbal and Alternative Treatments for Anxiety & Depression BZD Learning Objectives • List at least three uses for benzodiazepines • Discuss at least two risk factors associated with benzodiazepine prescriptions Craig Strickland, PhD, Owner Biobehavioral Education and Consultation https://sites.google.com/site/bioedcon 1 2 BZD Pharmacokinetics Clinical Uses of BZDs Generic Name Trade Name Rapidity ½ Life Dose (mg) • Treat a variety of anxiety disorders alprazolam Xanax Intermediate Short 0.75-4 • Hypnotics • Muscle relaxants chlordiaze- Librium Intermediate Long 15-100 poxide • To produce anterograde amnesia clonazepam Klonopin Intermediate Long 0.5-4 • Alcohol & other CNS depressant withdrawal • Anti-convulsant therapy diazepam Valium Rapid Long 4-40 triazolam Halcion Intermediate Very short 0.125-0.5 temazepam Restoril Short Short 7.5-30 3 4 1 2019 PCB Conference: Strickland Issues with BZDs Herbal Medication and Alternative Therapies Used in the Treatment of Depression and Anxiety • Addictive potential • Confusion between “anti-anxiety” effects and the “warm-fuzzy) • Large dose ranges • Comparison of BZDs with medications like Buspar, etc. • They work, they work well and they work quickly 5 6 Alternative Tx. Learning Objectives Background Information on herbals: Natural does not necessarily mean “safe” • List several amino acid treatments for depression • Side-effects and adverse reactions • List at least three of the most common herbal – Herbal medications are “drugs” although
    [Show full text]
  • Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin Healthcare
    Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin healthcare 4/22/2020 Overview benzodiazepines • Examples of benzos and benzo like drugs • Indications for benzos • Pharmacology of benzos • Side effects and contraindications • Benzo withdrawal • Benzo tapers 12/06/2018 Sedative/Hypnotics • Benzodiazepines • Alcohol • Z-drugs (Benzo-like sleeping aids) • Barbiturates • GHB • Propofol • Some inhalants • Gabapentin? Pregabalin? 12/06/2018 Examples of benzodiazepines • Midazolam (Versed) • Triazolam (Halcion) • Alprazolam (Xanax) • Lorazepam (Ativan) • Temazepam (Restoril) • Oxazepam (Serax) • Clonazepam (Klonopin) • Diazepam (Valium) • Chlordiazepoxide (Librium) 4/22/2020 Sedatives: gaba stimulating drugs have incomplete “cross tolerance” 12/06/2018 Effects from sedative (Benzo) use • Euphoria/bliss • Suppresses seizures • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Sleep inducing • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 Tolerance to benzo effects? • Effects quickly diminish with repeated use (weeks) • Euphoria/bliss • Suppresses seizures • Effects incompletely diminish with repeated use • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Seep inducing • Durable effects with repeated use • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 If you understand this pharmacology you can figure out the rest... • Potency • 1 mg diazepam <<< 1 mg alprazolam • Duration of action • Half life differences • Onset of action • Euphoria, clinical utility in acute
    [Show full text]
  • Deliberate Self-Poisoning with a Lethal Dose of Pentobarbital: Survival with Supportive Care
    Deliberate self-poisoning with a lethal dose of pentobarbital: Survival with supportive care. (1) (1,2) Santosh Gone , Andis Graudins (1) Clinical Toxicology Service, Program of Emergency Medicine, Monash Health (2) Monash Emergency Research Collaboration, Clinical Sciences at Monash Health, Monash University Abstract 84 INTRODUCTION CASE REPORT (continued) DISCUSSION Pentobarbital (Nembutal) is short acting In the ED: Pentobarbital has been a banned substance for barbiturate sedative-hypnotic, currently widely GCS: 3/15, fixed dilated pupils, apnoeic and human use in Australia since 1998. However, it can used in veterinary practice for anesthesia and ventilated. be procured overseas or bought on the internet. euthanasia. Pulse: 116 bpm sinus tachycardia BP: 115/60 on epinephrine infusion. Pentobarbital is recommended as an effective It is also commonly recommended as a VBG: pH 7.03 pCO2 77 mmHg Bicarb 19 mmol/L agent for use in euthanasia due to its apparently euthanasia drug for assisted suicide and it is Lactate 8.8 mmol/L peaceful transition to death. unlikely that any resuscitative measures will be Activated charcoal (50g) given via an NG tube. attempted in such cases. Course in the Intensive Care Department: In a case series of 150 assisted suicides in Day-1 post-OD: Sweden, a 100% success rate was seen with Intentional overdose results in depression of - Absent brain stem reflexes and fixed dilated pupils for ingestion of 9 grams. Cardiovascular collapse was brain stem function and rapid onset respiratory five days. seen within 15 minutes in 30% of patients. It is rare depression and apnoea. Hypotension also - Diabetes insipidus developed with urine output of to see survival after intentional ingestion for develops, followed by cardiovascular collapse 300ml/hour.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Choice of Drugs in the Treatment of Rheumatoid Arthritis
    RHEUMATOLOGY IN GENERAL PRACTICE 7 Those with predominant but never exclusive involvement of the terminal finger joint, usually associated with changes in the nail of the same finger; they are serologically negative. There may be a swollen finger with loss of the skin markings-a sort of dactylitis, again serologically negative. (2) Those with a much more severe process which produces loss of movement in the spine and changes in the sacroiliac joints much the same as those in ankylosing spondylitis; unlike ankylosing spondylitis, it produces severe deformity often with ankylosis in peripheral joints. Many of the finger joints become deformed and ankylosed. (3) Those cases indistinguishable from rheumatoid arthritis although the majority are sero-negative. The Stevens Johnson syndrome produces acute effusions, particularly in large joints. It is sometimes associated with the rash of erythema multiforme, always with ulceration in the mouth and genital tract; the mouth ulcers are accompanied by sloughing, unlike those of Beh9et's syndrome which we come to next. BehCet's syndrome, originally described as a combination of orogenital ulceration with relapsing iritis, is now expanded to include skin lesions, other eye lesions, lesions of the central nervous system, thrombophlebitis migrans, and arthropathy (occurring in 64 per cent). The onset is acute, often affecting only a single joint and settling without residual trouble. Choice of drugs in the treatment of rheumatoid arthritis Dr Dudley Hart, M.D., F.R.C.P. (Consultant physician, Westminster Hospital and Medical School) There are many potential drugs for the treatment of rheumatoid disease, but what are we treating in this disorder? Pain in rheumatoid arthritis is but one of the symp- toms.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Inhibiting Progesterone Metabolism in the Hippocampus of Rats in Behavioral Estrus Decreases Anxiolytic Behaviors and Enhances E
    Cognitive, Affective, & Behavioral Neuroscience 2001, 1 (3), 287-296 Inhibiting progesterone metabolism in the hippocampus of rats in behavioral estrus decreases anxiolytic behaviors and enhances exploratory and antinociceptive behaviors MADELINE E. RHODES and CHERYL A. FRYE State University of New York, Albany, New York Blocking progesterone’s metabolism to 5a -pregnan-3a -ol-20-one (3a ,5a -THP) with finasteride, a 5a -reductase inhibitor, and effects on anxiolytic, exploratory, and antinociceptive behaviors of rats in behavioral estrus were examined. Rats in behavioral estrus received finasteride systemically (SC), to the hippocampus, or to control implant sites, the nucleus accumbens (NA) or ventral tegmental area (VTA), and were tested in horizontal crossing, open-field, elevated plus-maze, emergence, holeboard, social interaction, tailflick, pawlick, and defensive freezing tasks. Finasteride, SC or intrahippocampally, reduced 3a ,5a -THP in the hippocampus relative to vehicle implants or finasteride to the NA or VTA. Systemic or intrahippocampal finasteride decreasedcentral entries in the open field and open-arm time on the elevated plus-maze and increasedfreezing in response to shock relative to vehicle. Finasteride to the hippocampus decreased emergence latencies and increased social interaction, pawlick, and tail- flick latencies relative to all other groups. Finasteride to the hippocampus of rats in behavioral estrous decreased anxiolysis and enhanced exploration and analgesia. In summary, these data demonstrate that decreasesin anxiolytic behavior of behavioral estrous rats can be produced by reductions in 3a ,5a - THP in the hippocampus, which suggest that elevations in 3a ,5a -THP in the hippocampus may give rise to anxiolysis seen during behavioral estrus. There are sex differences, as well as differences across Guasti et al., 1999; Fernandez-Guasti & Picazo, 1990; the ovarian cycle, in rodents on performance in anxiety Frye et al., 2000).
    [Show full text]
  • Piper Methysticum) in Rats
    Graduate Theses, Dissertations, and Problem Reports 2008 Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R. Bruner West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Bruner, Natalie R., "Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats" (2008). Graduate Theses, Dissertations, and Problem Reports. 4358. https://researchrepository.wvu.edu/etd/4358 This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R. Bruner Thesis submitted to the Eberly College of Arts and Sciences at West Virginia University in Partial Fulfillment of the Requirements for the Degree of Master of Science in Psychology Karen G. Anderson, Ph. D., Chair Kennon A. Lattal, Ph.D. Hawley Montgomery-Downs, Ph.D. Department of Psychology Morgantown, WV 2008 Keywords: drug discrimination, kava, chlordiazepoxide ABSTRACT Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R.
    [Show full text]
  • INTRAVENOUS ANAESTHESIA Dr
    INTRAVENOUS ANAESTHESIA Dr. SK Sharma, Associate Professor General anaesthesia: It is the controlled, reversible intoxication of CNS producing unconsciousness with complete loss of sensory as well as motor reflexes. The common methods to induce GA in animals are by using inhalation and intravenous anaesthesia. The other not so common methods are oral. Per rectal, intramuscular, intra peritoneum etc. However out of these methods the most preferred method is intravenous anaesthesia. Intravenous anaesthesia: Intravenous anaesthesia in veterinary practice is primarily used for the induction of anaesthesia which is subsequently maintained by inhalation anaesthesia in small animals. However in large animals intravenous anaesthesia is mostly used for both induction as well as maintenance of anaesthesia. Advantages: 1. Easiness in administration. 2. Produces surgical anaesthesia with speed and pleasantness. 3. No sophisticated facilities are required as for inhalation anaesthesia. 4. Requires minimum equipment. 5. Economical Disadvantages: 1. Recovery depends upon the ability of the animal to redistribute, metabolize and excrete the anaesthetic drug. Very important in sick and debilitatedDr. animals. SK Sharma 2. Depth of anaesthesia cannot be decreased quickly unless you have an antagonist. 3. Recovery period may be longer depending upon the health status of the animal and the drug used. 4. Characteristic excitement and premature attempts to stand during recovery may be dangerous sometimes. 5. Long procedures can lead to severe physiological changes in the patient. 6. Oxygen and assisted controlled ventilation may not be available during emergency. 2 RUMONANTS ARE POOR SUBJECTS FOR INTRAVENOUS ANAESTHESIA. WHY? The ruminants are considered as poor subjects for general anaesthesia by any method because of many reasons as listed below: 1.
    [Show full text]
  • GENERAL ANAESTHESIA Anesthetic Period
    GENERAL ANAESTHESIA Dr.Hiba A. Shekho 4th Stage General anesthesia:- a state of total unconsciousness resulting from anesthetic drugs (as for a major surgical operation). Anesthetic period:- The anesthetic period can be divided into five phases:- Phase 1 :Preoperative period: The animal is examined and an anesthetic protocol devised by the veterinary surgeon to minimize the risk to the individual animal. The animal’s health, the type of procedure, the ability and experience of both the anesthetist and the surgeon are all factors that should be considered. The area for induction and maintenance of anesthesia must be clean and prepared. phase 2: Pre-anesthetic period: Pre-anaesthetic medication is given as part of a balanced anesthetic protocol. Sedatives and analgesics are used to reduce anxiety, relieve discomfort, enable a smooth induction and reduce the requirement for high doses of anesthetic induction and maintenance agents. The animal should be allowed to remain undisturbed following administration of the pre-anesthetic agents, although close observation during this period is recommended. Phase 3:Induction period: Anesthesia should be induced in a calm and quiet environment. Placement of an intravenous catheter allows for ease of administration of intravenous agents and prevents the risk of extravascular injection of irritant drugs. To ensure a smooth transition from induction to maintenance, appropriate endotracheal tubes, anesthetic breathing system and ancillary equipment must be prepared for use. Suitable intravenous fluids should be administered during anesthesia. Phase 4:Maintenance period: Unconsciousness is maintained with inhalational or injectable agents. This allows the planned procedure to be performed. A properly trained person should be dedicated to monitor anesthesia.
    [Show full text]